{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:26:23Z","timestamp":1792074383999,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>After neoadjuvant chemotherapy (NACT) of breast cancer, an accurate response assessment is essential for the de-escalation of surgical therapy. This study evaluated whether breast imaging procedures can reliably predict a pathologic complete response (pCR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, monocenter study included 388 cases of invasive breast cancer treated by NACT. Most of the patients received mammography (MG) and ultrasound (US). In some cases, magnetic resonance imaging (MRI) was performed for special indications. The absence of residual tumor on imaging was defined as clinical complete response (cCR). Minimal signs of residual tumor were categorized as near-cCR. The primary endpoints were negative predictive values (NPVs) and false-negative rates (FNRs) of all imaging methods, combined and separately, for the whole cohort and subgroups of triple-negative (TN), human epidermal growth factor 2-positive (HER2+), and hormone receptor-positive (HR+)\/HER2\u2013 breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The overall pCR rate was 40.7 %, with most pCR cases having triple-negative breast cancer (TNBC) (\n                      <jats:italic>n<\/jats:italic>\n                      = 85, 57.8 %). The highest NPV (71.6 %) and the lowest FNR (11.0 %) in the overall cohort were achieved by the combination of ultrasound and mammography. In the TNBC subgroup, NPVs ranged from 78.1 % to 83.7 %, compared with lower NPVs in the HR+ subgroup (34.2\u201350.0 %). If near-cCR cases were defined together with cCR as a \u201cnegative\u201d test result, the predictive accuracy of imaging decreased in the whole cohort (FNR, 34.8 %; NPV, 56.1 %).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Standard imaging is insufficient to predict pCR reliably in an unselected cohort. Strict patient selection and additional diagnostics are necessary for safe confirmation of pCR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-19670-6","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:22:09Z","timestamp":1777900929000},"page":"7206-7215","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictive Value of Routine Imaging for the Diagnosis of Pathologic Complete Response After Neoadjuvant Chemotherapy in Breast Cancer"],"prefix":"10.1245","volume":"33","author":[{"given":"Maria","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Heil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Pfob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lie","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Reisig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riku","family":"Togawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Hennigs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Riedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Stieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Feisst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Nees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Zivanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Golatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Sch\u00e4fgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"19670_CR1","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdz235","volume":"30","author":"HJ Burstein","year":"2019","unstructured":"Burstein HJ, Curigliano G, Loibl S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30:1541\u201357. https:\/\/doi.org\/10.1093\/annonc\/mdz235.","journal-title":"Ann Oncol."},{"key":"19670_CR2","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1245\/s10434-011-2108-2","volume":"19","author":"M Kaufmann","year":"2012","unstructured":"Kaufmann M, von Minckwitz G, Mamounas EP, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012;19:1508\u201316. https:\/\/doi.org\/10.1245\/s10434-011-2108-2.","journal-title":"Ann Surg Oncol."},{"key":"19670_CR3","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1002\/ijc.33122","volume":"147","author":"F Riedel","year":"2020","unstructured":"Riedel F, Hoffmann AS, Moderow M, et al. Time trends of neoadjuvant chemotherapy for early breast cancer. Int J Cancer. 2020;147:3049\u201358. https:\/\/doi.org\/10.1002\/ijc.33122.","journal-title":"Int J Cancer."},{"key":"19670_CR4","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1245\/s10434-018-6531-5","volume":"25","author":"BL Murphy","year":"2018","unstructured":"Murphy BL, Day CN, Hoskin TL, Habermann EB, Boughey JC. Neoadjuvant chemotherapy use in breast cancer is greatest in excellent responders: triple-negative and HER2+ subtypes. Ann Surg Oncol. 2018;25:2241\u20138. https:\/\/doi.org\/10.1245\/s10434-018-6531-5.","journal-title":"Ann Surg Oncol."},{"key":"19670_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10549-016-4016-4","volume":"160","author":"A Hennigs","year":"2016","unstructured":"Hennigs A, Riedel F, Marm\u00e9 F, et al. Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade. Breast Cancer Res Treat. 2016;160:491\u20139. https:\/\/doi.org\/10.1007\/s10549-016-4016-4.","journal-title":"Breast Cancer Res Treat."},{"key":"19670_CR6","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10549-018-4801-3","volume":"170","author":"W Haque","year":"2018","unstructured":"Haque W, Verma V, Hatch S, Suzanne Klimberg V, Brian Butler E, Teh BS. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Res Treat. 2018;170:559\u201367. https:\/\/doi.org\/10.1007\/s10549-018-4801-3.","journal-title":"Breast Cancer Res Treat."},{"key":"19670_CR7","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1016\/j.ejca.2012.05.023","volume":"48","author":"N Houssami","year":"2012","unstructured":"Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012;48:3342\u201354. https:\/\/doi.org\/10.1016\/j.ejca.2012.05.023.","journal-title":"Eur J Cancer."},{"key":"19670_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10549-017-4155-2","volume":"163","author":"B Goorts","year":"2017","unstructured":"Goorts B, van Nijnatten TJ, de Munck L, et al. Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2017;163:83\u201391. https:\/\/doi.org\/10.1007\/s10549-017-4155-2.","journal-title":"Breast Cancer Res Treat."},{"key":"19670_CR9","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00066-020-01641-9","volume":"196","author":"F Dierks","year":"2020","unstructured":"Dierks F, Pietsch E, Dunst J. [Pembrolizumab as neoadjuvant treatment of early triple-negative breast cancer]. Pembrolizumab in der neoadjuvanten Behandlung des fr\u00fchen triple-negativen Mammakarzinoms. Strahlenther Onkol. 2020;196:841\u20133. https:\/\/doi.org\/10.1007\/s00066-020-01641-9.","journal-title":"Strahlenther Onkol."},{"key":"19670_CR10","unstructured":"Deutsche Krebsgesellschaft DK, AWMF. S3-Leitlinie Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.4, 2021, AWMF Registernummer: 032-045OL. http:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/mammakarzinom\/ 2021."},{"key":"19670_CR11","doi-asserted-by":"publisher","first-page":"7421","DOI":"10.1245\/s10434-021-10117-8","volume":"28","author":"FK Palshof","year":"2021","unstructured":"Palshof FK, Lanng C, Kroman N, et al. Prediction of pathologic complete response in breast cancer patients comparing magnetic resonance imaging with ultrasound in neoadjuvant setting. Ann Surg Oncol. 2021;28:7421\u20139. https:\/\/doi.org\/10.1245\/s10434-021-10117-8.","journal-title":"Ann Surg Oncol."},{"key":"19670_CR12","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.2147\/cmar.S247279","volume":"12","author":"K Zhang","year":"2020","unstructured":"Zhang K, Li J, Zhu Q, Chang C. Prediction of pathologic complete response by ultrasonography and magnetic resonance imaging after neoadjuvant chemotherapy in patients with breast cancer. Cancer Manage Res. 2020;12:2603\u201312. https:\/\/doi.org\/10.2147\/cmar.S247279.","journal-title":"Cancer Manage Res."},{"key":"19670_CR13","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1245\/s10434-015-4918-0","volume":"23","author":"B Schaefgen","year":"2016","unstructured":"Schaefgen B, Mati M, Sinn HP, et al. Can routine imaging after neoadjuvant chemotherapy in breast cancer predict pathologic complete response? Ann Surg Oncol. 2016;23:789\u201395. https:\/\/doi.org\/10.1245\/s10434-015-4918-0.","journal-title":"Ann Surg Oncol."},{"key":"19670_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10549-005-2510-1","volume":"92","author":"AF Schott","year":"2005","unstructured":"Schott AF, Roubidoux MA, Helvie MA, et al. Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2005;92:231\u20138. https:\/\/doi.org\/10.1007\/s10549-005-2510-1.","journal-title":"Breast Cancer Res Treat."},{"key":"19670_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1055\/s-0043-124082","volume":"78","author":"H Richter","year":"2018","unstructured":"Richter H, Hennigs A, Schaefgen B, et al. Is breast surgery necessary for breast carcinoma in complete remission following neoadjuvant chemotherapy? Geburtshilfe Frauenheilkd. 2018;78:48\u201353. https:\/\/doi.org\/10.1055\/s-0043-124082.","journal-title":"Geburtshilfe Frauenheilkd."},{"key":"19670_CR16","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1245\/s10434-011-1919-5","volume":"18","author":"R Croshaw","year":"2011","unstructured":"Croshaw R, Shapiro-Wright H, Svensson E, Erb K, Julian T. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients. Ann Surg Oncol. 2011;18:3160\u20133. https:\/\/doi.org\/10.1245\/s10434-011-1919-5.","journal-title":"Ann Surg Oncol."},{"key":"19670_CR17","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1245\/s10434-006-9086-9","volume":"13","author":"F Peintinger","year":"2006","unstructured":"Peintinger F, Kuerer HM, Anderson K, et al. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol. 2006;13:1443\u20139. https:\/\/doi.org\/10.1245\/s10434-006-9086-9.","journal-title":"Ann Surg Oncol."},{"key":"19670_CR18","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.amjsurg.2009.03.012","volume":"199","author":"JD Keune","year":"2010","unstructured":"Keune JD, Jeffe DB, Schootman M, Hoffman A, Gillanders WE, Aft RL. Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer. Am J Surg. 2010;199:477\u201384. https:\/\/doi.org\/10.1016\/j.amjsurg.2009.03.012.","journal-title":"Am J Surg."},{"key":"19670_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.breast.2018.02.028","volume":"39","author":"A Baumgartner","year":"2018","unstructured":"Baumgartner A, Tausch C, Hosch S, et al. Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast. 2018;39:19\u201323. https:\/\/doi.org\/10.1016\/j.breast.2018.02.028.","journal-title":"Breast."},{"key":"19670_CR20","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1002\/cncr.27995","volume":"119","author":"JF De Los Santos","year":"2013","unstructured":"De Los Santos JF, Cantor A, Amos KD, et al. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. Cancer. 2013;119:1776\u201383. https:\/\/doi.org\/10.1002\/cncr.27995.","journal-title":"Cancer."},{"key":"19670_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2019.108701","volume":"120","author":"EMS Negr\u00e3o","year":"2019","unstructured":"Negr\u00e3o EMS, Souza JA, Marques EF, Bitencourt AGV. Breast cancer phenotype influences MRI response evaluation after neoadjuvant chemotherapy. Eur J Radiol. 2019;120:108701. https:\/\/doi.org\/10.1016\/j.ejrad.2019.108701.","journal-title":"Eur J Radiol."},{"key":"19670_CR22","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1111\/ans.16966","volume":"91","author":"AA Winder","year":"2021","unstructured":"Winder AA, Dijkstra B. Is pathological complete response predictable after neoadjuvant chemotherapy in breast cancer? A single institution\u2019s retrospective experience. ANZ J Surg. 2021;91:1779\u201383. https:\/\/doi.org\/10.1111\/ans.16966.","journal-title":"ANZ J Surg."},{"key":"19670_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2020.109468","volume":"135","author":"F Riedel","year":"2021","unstructured":"Riedel F, Schaefgen B, Sinn HP, et al. Diagnostic accuracy of axillary staging by ultrasound in early breast cancer patients. Eur J Radiol. 2021;135:109468. https:\/\/doi.org\/10.1016\/j.ejrad.2020.109468.","journal-title":"Eur J Radiol."},{"key":"19670_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113500","volume":"198","author":"IT Rubio","year":"2024","unstructured":"Rubio IT, Marotti L, Biganzoli L, et al. EUSOMA quality indicators for non-metastatic breast cancer: an update. Eur J Cancer. 2024;198:113500. https:\/\/doi.org\/10.1016\/j.ejca.2023.113500.","journal-title":"Eur J Cancer."},{"key":"19670_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejca.2017.08.017","volume":"86","author":"L Biganzoli","year":"2017","unstructured":"Biganzoli L, Marotti L, Hart CD, et al. Quality indicators in breast cancer care: an update from the EUSOMA working group. Eur J Cancer. 2017;86:59\u201381. https:\/\/doi.org\/10.1016\/j.ejca.2017.08.017.","journal-title":"Eur J Cancer."},{"key":"19670_CR26","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/jco.20.03399","volume":"39","author":"LA Korde","year":"2021","unstructured":"Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39:1485\u2013505. https:\/\/doi.org\/10.1200\/jco.20.03399.","journal-title":"J Clin Oncol."},{"key":"19670_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10549-018-4912-x","volume":"172","author":"CRF Barbosa","year":"2018","unstructured":"Barbosa CRF, Falcone AB, Buzaid AC, Pimenta JM, Schvartsman G, Frasson AL. Neoadjuvant therapy for breast cancer treatment: an expert panel recommendation from the Brazilian Society of Breast Surgeons 2018. Breast Cancer Res Treat. 2018;172:265\u201372. https:\/\/doi.org\/10.1007\/s10549-018-4912-x.","journal-title":"Breast Cancer Res Treat."},{"key":"19670_CR28","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10549-023-06986-0","volume":"201","author":"DT Hamersma","year":"2023","unstructured":"Hamersma DT, Schreuder K, Geleijnse G, et al. Comparing quality of breast cancer care in the Netherlands and Norway by federated propensity score analytics. Breast Cancer Res Treat. 2023;201:247\u201356. https:\/\/doi.org\/10.1007\/s10549-023-06986-0.","journal-title":"Breast Cancer Res Treat."},{"key":"19670_CR29","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/jco.2011.38.8595","volume":"30","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796\u2013804. https:\/\/doi.org\/10.1200\/jco.2011.38.8595.","journal-title":"J Clin Oncol."},{"key":"19670_CR30","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer."},{"key":"19670_CR31","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1186\/s12885-018-4760-4","volume":"18","author":"J Heil","year":"2018","unstructured":"Heil J, Sinn P, Richter H, et al. RESPONDER: diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer: a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial. BMC Cancer. 2018;18:851. https:\/\/doi.org\/10.1186\/s12885-018-4760-4.","journal-title":"BMC Cancer."},{"key":"19670_CR32","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/sla.0000000000004246","volume":"275","author":"J Heil","year":"2022","unstructured":"Heil J, Pfob A, Sinn HP, et al. Diagnosing pathologic complete response in the breast after neoadjuvant systemic treatment of breast cancer patients by minimal invasive biopsy: oral presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, program number GS5-03. Ann Surg. 2022;275:576\u201381. https:\/\/doi.org\/10.1097\/sla.0000000000004246.","journal-title":"Ann Surg."},{"key":"19670_CR33","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1245\/s10434-021-10847-9","volume":"29","author":"V Koelbel","year":"2022","unstructured":"Koelbel V, Pfob A, Schaefgen B, et al. Vacuum-assisted breast biopsy after neoadjuvant systemic treatment for reliable exclusion of residual cancer in breast cancer patients. Ann Surg Oncol. 2022;29:1076\u201384. https:\/\/doi.org\/10.1245\/s10434-021-10847-9.","journal-title":"Ann Surg Oncol."},{"key":"19670_CR34","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1245\/s10434-023-14551-8","volume":"31","author":"A Pfob","year":"2024","unstructured":"Pfob A, Cai L, Schneeweiss A, et al. Minimally invasive breast biopsy after neoadjuvant systemic treatment to identify breast cancer patients with residual disease for extended neoadjuvant treatment: a new concept. Ann Surg Oncol. 2024;31:957\u201365. https:\/\/doi.org\/10.1245\/s10434-023-14551-8.","journal-title":"Ann Surg Oncol."},{"key":"19670_CR35","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ejca.2020.11.006","volume":"143","author":"A Pfob","year":"2021","unstructured":"Pfob A, Sidey-Gibbons C, Lee HB, et al. Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy. Eur J Cancer. 2021;143:134\u201346. https:\/\/doi.org\/10.1016\/j.ejca.2020.11.006.","journal-title":"Eur J Cancer."},{"key":"19670_CR36","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1200\/jco.21.02439","volume":"40","author":"A Pfob","year":"2022","unstructured":"Pfob A, Sidey-Gibbons C, Rauch G, et al. Intelligent vacuum-assisted biopsy to identify breast cancer patients with pathologic complete response (ypT0 and ypN0) after neoadjuvant systemic treatment for omission of breast and axillary surgery. J Clin Oncol. 2022;40:1903\u201315. https:\/\/doi.org\/10.1200\/jco.21.02439.","journal-title":"J Clin Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19670-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19670-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19670-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:42:30Z","timestamp":1783345350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19670-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["19670"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19670-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"5 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}